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Abstract
The NEDD8-activating enzyme (NAE) initiates neddylation, the cascade of post-translational NEDD8 conjugation onto target
proteins. MLN4924, a selective NAE inhibitor, has displayed preclinical anti-tumor activity in vitro and in vivo, and promising
clinical activity has been reported in patients with refractory hematologic malignancies. Here, we sought to understand the
mechanisms of resistance to MLN4924. K562 and U937 leukemia cells were exposed over a 6 month period to MLN4924 and
populations of resistant cells (R-K562MLN, R-U937MLN) were selected. R-K562MLN and R-U937MLN cells contain I310N and
Y352H mutations in the NAE catalytic subunit UBA3, respectively. Biochemical analyses indicate that these mutations
increase the enzyme’s affinity for ATP while decreasing its affinity for NEDD8. These mutations effectively contribute to
decreased MLN4924 potency in vitro while providing for sufficient NAE function for leukemia cell survival. Finally, R-K562MLN
cells showed cross-resistance to other NAE-selective inhibitors, but remained sensitive to a pan-E1 (activating enzyme)
inhibitor. Thus, our work provides insight into mechanisms of MLN4924 resistance to facilitate the development of more
effective second-generation NAE inhibitors.
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Introduction
Ubiquitin (Ub) and ubiquitin-like proteins (Ubls), such as neural
precursor cell-expressed developmentally downregulated 8
(NEDD8) and small ubiquitin-related modifier (SUMO), are
essential mediators of cellular function [1,2,3]. Through multi-
step enzymatic cascades, Ub and Ubls are conjugated onto target
proteins, marking them for various fates such as degradation,
translocation, signaling and regulation of transcriptional activity
[4,5,6,7]. In the case of NEDD8, the cascade of its conjugation to
target proteins (i.e., neddylation) is initiated by the E1 NEDD8-
activating enzyme (NAE), which is a heterodimeric molecule
consisting of NAEa (also known as amyloid beta precursor
protein-binding protein 1, APPBP1) and NAEb (also known as
ubiquitin-like modifier activating enzyme 3, UBA3). In the first
step of the cascade, NAE binds ATP and NEDD8 and catalyzes
the formation of a NEDD8-AMP intermediate, which binds the
adenylation domain of NAE. NEDD8-AMP reacts with the
catalytic cysteine in UBA3 during which NEDD8 is transferred to
the catalytic cysteine, resulting in a high energy thiolester linkage.
NAE then binds ATP and NEDD8 to generate a second NEDD8-
AMP, forming a fully-loaded NAE carrying two activated NEDD8
molecules (i.e., one as a thioester and the other as an adenylate)
[8,9,10]. The thioester-bound NEDD8 is subsequently transferred
onto the catalytic cysteine of an E2 NEDD8-conjugating enzyme
and finally covalently conjugated to lysine residues of substrate
proteins with the help of an E3 NEDD8 ligase.
Mediating cross-talk between Ub and Ubl pathways, neddyla-
tion plays a crucial role in the assembly and function of members
of the largest family of E3 Ub ligases, the cullin-RING ligases
(CRLs). CRLs target a plethora of cellular proteins for ubiquitina-
tion and proteasomal degradation, including a number of
substrates such as IkBa and p27 that play important roles in
cancer progression [11,12,13,14,15,16].
Recently, The Takeda Oncology Company: Millennium
reported the development of an AMP mimetic, MLN4924, which
selectively inhibits NAE [17]. This compound is not a simple
substrate-competitive inhibitor; its inhibitory activity is mecha-
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nism-based [18]. MLN4924 forms a stable covalent adduct with
NEDD8 in the NAE catalytic pocket by reacting with thiolester-
linked NEDD8 bound to the enzyme’s catalytic cysteine. Unlike
the labile NEDD8-AMP intermediate, the NEDD8-MLN4924
adduct cannot be utilized in subsequent reactions necessary for
NAE activity.
Inhibition of NAE by MLN4924 in human cancer cells results
in uncontrolled S-phase DNA replication leading to DNA damage
and subsequent cell death through apoptosis [17,19,20].
MLN4924 shows potent anti-tumor activity in human solid
epithelial tumor xenografts [17], and also displays preclinical
activity in vitro and in vivo in hematologic malignancies, including
leukemia [21,22,23]. Currently, this drug is being evaluated in
early phase clinical trials in patients with refractory hematologic
malignancies including leukemia [24], where it is showing
promising clinical efficacy in refractory patients [25]. While still
in the early stages of clinical development, the encouraging
preclinical and clinical activity of MLN4924 supports investigation
into the mechanisms of sensitivity and resistance to this drug
[26,27].
In this report, we describe two previously unreported and
uncharacterized novel mutations in the UBA3 gene in two
leukemia cell lines with acquired resistance to MLN4924. We
demonstrate that these mutations decrease sensitivity of NAE to
the drug by changing the biochemical properties of the enzyme
without impairing its normal enzymatic function. Interestingly, the
MLN4924-resistant cells remain sensitive to a pan-E1 inhibitor
known as Compound 1 that is structurally related to MLN4924.
Thus, through this study, we have gained important insights into
the function of NAE and the basis for the selectivity of NAE
inhibitors. In addition, this work will help in the rational
development of novel NAE inhibitors to overcome or circumvent
resistance to MLN4924.
Materials and Methods
Compounds, MLN4924-resistant cell lines and patient
samples
MLN4924 and Compound 1 were obtained and prepared as
described in ‘‘Supporting Information Methods in File S1’’. K562
[28] and U937 [29] human leukemia cell lines were obtained as a
kind gift from Dr. Kamel-Reid and Dr. Minden (Princess
Margaret Cancer Centre, Toronto, ON, Canada), respectively.
Both cell lines were authenticated with short tandem repeat (STR)
method in September 2011. In addition, cell lines were
periodically authenticated by morphologic inspection. K562 and
U937 cell lines were cultured in media containing stepwise
increasing concentrations of MLN4924 and resistance was
periodically assessed by cell viability assay as described in
‘‘Supporting Information Methods in File S1’’. K562 and U937
cells that grew normally in the presence of 250 nM or 200 nM
MLN4924, respectively, were used for further analysis. NEDD8
knockdown was accomplished as detailed in ‘‘Supporting Infor-
mation Methods in File S1’’. Mononuclear cells from an AML
patient were isolated from the peripheral blood and bone marrow
by Histopaque-1077-gradient density centrifugation. The collec-
tion and use of human tissue was approved by local ethics review
boards (University Health Network, Toronto, ON, Canada;
Stanford University, Palo Alto, CA, Protocol no.18329). The
AML patient sample was collected at the Stanford Medical Centre
with written informed consent and obtained for this study from the
Stanford Hematology Division Tissue Bank (https://
clinicalinformatics.stanford.edu/projects/hematology.html).
Immunoblot analyses
Cells were prepared for immunoblot analysis as described in
‘‘Supporting Information Methods in File S1’’. Immunoblots were
performed with anti-NEDD8, anti-ubiquitin (Cell Signaling
Technology) and anti-a-tubulin (Calbiochem).
DNA sequencing
NEDD8 (NM_006156) and UBA3 (NM_003968) cDNAs were
amplified by Q-RT-PCR as previously described [30] using the
primers listed in Table S1 in File S1. PCR products for NEDD8
(378 bp) and UBA3 (1480 bp) were gel-purified using the QIAEX
II Gel Extraction Kit (QIAGEN). Sequencing was performed at
the DNA Sequencing Facility of The Hospital for Sick Children
(Toronto, ON, Canada).
Recombinant protein production and kinetic analyses
The production of recombinant human UBA3 (isoform 1) and
NEDD8 were performed as described elsewhere [27] and in
‘‘Supporting Information Methods in File S1’’. UBA3 I310N and
UBA3 Y352H were generated using the QuikChange site-directed
mutagenesis kit (Agilent). NAE complexes containing UBA3,
UBA3 I310N, or UBA3 Y352H were purified by Ni-NTA
chromatography [27]. ATP:PPi exchange assays were based on
a previously published method [18,27,31] and performed essen-
tially as described [27], as detailed in ‘‘Supporting Information
Methods in File S1’’.
Results
Selection of K562 leukemia cells resistant to MLN4924
The human leukemia cell line K562 was chosen to explore the
molecular basis of acquired resistance to MLN4924, as this cell
line was sensitive to MLN4924-induced cytotoxicity with EC50
values of ,100 nM (Figure 1A). To generate K562 cells resistant
to MLN4924, cells were cultured over 6 months in the presence of
stepwise increasing concentrations of MLN4924 from 10 to 250
nM. After 6 months, a resistant population of K562 cells was
selected that were capable of growth in the presence of 250 nM
MLN4924. We termed this subline R-K562MLN and used it for
further characterization. To assess the degree of resistance to
MLN4924, parental and resistant cells were treated with
increasing concentrations of MLN4924. After 72 hours of
incubation, cell growth and viability were measured with the
CellTiter-Glo luminescence assay. As shown in dose-response
curves (Figure 1A), R-K562MLN cells were over 40-fold resistant
to MLN4924 compared to parental K562 cells. Despite their
resistance to MLN4924, R-K562MLN cells proliferated similarly to
parental K562 cells (Figure 1B). We also evaluated the stability of
resistance to MLN4924. R-K562MLN cells were cultured in the
absence of MLN4924 for 5 weeks, and sensitivity to MLN4924
was subsequently reassessed. R-K562MLN cells remained resistant
to MLN4924 even after withdrawal of the drug (Figure 1C).
MLN4924-resistant K562 leukemia cells remain sensitive
to a broad spectrum of chemotherapeutic drugs
In tumour cells, the multidrug resistance (MDR) phenotype is a
common mechanism that accounts for the simultaneous emer-
gence of resistance to a variety of anticancer drugs [32,33]. To
exclude the possibility of a generalized MDR phenotype as a
mechanism of resistance to MLN4924, we assessed whether R-
K562MLN cells demonstrated cross-resistance to other standard
chemotherapeutic agents. Parental and resistant cells were treated
with increasing concentrations of several chemotherapeutic drugs
UBA3 Mutations Confer Resistance to MLN4924 in AML
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with distinct mechanisms of action, including daunorubicin,
cytarabine, and etoposide. Compared to parental cells, R-
K562MLN cells are similarly sensitive to all of the agents tested
(Figure 1D). Of note, daunorubicin is among the classical
substrates of the multidrug efflux transporter P-glycoprotein (P-gp,
also known as ABCB1) [33]. The lack of cross-resistance to these
drugs in R-K562MLN cells argues against a mechanism of
resistance to MLN4924 related to an MDR phenotype. Thus,
the mechanism of resistance to MLN4924 appears specific for this
agent and not related to generalized multidrug efflux.
Cullin neddylation is refractory to MLN4924 in K562-
resistant cells
Cullin proteins are the major substrates of the neddylation
pathway, and a characteristic feature of NAE activity is the
generation of NEDD8-conjugated cullin proteins. We therefore
examined the effects of MLN4924 on the levels of these conjugates
in parental and resistant cells. Cells were treated for 24 hours with
increasing concentrations of MLN4924, and the steady-state
abundance of NEDD8-conjugated cullins were assessed by
immunoblotting. As shown in Figure 2, the steady state levels of
NEDD8-cullins were equivalent in parental and resistant cells.
NEDD8-conjugated cullins were diminished in parental cells
treated with 25 nM MLN4924 (Figure 2A). In contrast, no
appreciable reduction in NEDD8-conjugated cullins was observed
in R-K562MLN cells after treatment with up to 250 nM MLN4924
(Figure 2A).
NEDD8 is essential for the survival of MLN4924-resistant
K562 leukemia cells
To ascertain if the components of the neddylation pathway are
intact in MLN4924-resistant cells, we used shRNA to knock down
expression of NEDD8 proteins in R-K562MLN cells. Cells were
infected with lentiviral vectors encoding NEDD8 shRNA or
control sequences. Knockdown of NEDD8 proteins was confirmed
by immunoblotting (Figure 2B). Knockdown of NEDD8 reduced
the steady state abundance of NEDD8-cullins (Figure 2B).
Moreover, knockdown of NEDD8 was cytotoxic to MLN4924-
resistant R-K562MLN cells (Figure 2C). These results suggest
NEDD8 conjugation remains necessary for the survival of resistant
cells.
MLN4924-resistant K562 cells harbor missense point
mutations in UBA3
To search for mechanisms of resistance to MLN4924 in the
resistant cell line, we sequenced the coding region of NEDD8 and
the catalytic subunit of NAE, UBA3, from K562 parental and R-
K562MLN cells. No mutations were identified in the NEDD8 gene.
However, we identified two missense point mutations in the UBA3
coding region in R-K562MLN cells: an A.T mutation in codon 8
Figure 1. MLN4924-resistant K562 (R-K562MLN) leukemia cells show decreased sensitivity to MLN4924, but not all chemother-
apeutics. A) Cells (56103 cells/well) were seeded in 96-well plates and treated with increasing concentrations of MLN4924 for 72 hours. After
treatment, cell growth and viability were determined by the CellTiter-Glo luminescence assay. Values shown are the mean percentage 6 SD of viable
cells relative to controls. B) Cells (16105/ml) were plated in 6-well plates. After incubation, cells were stained with trypan blue and counted at the
time points indicated. R-K562MLN cells were incubated in the presence or absence of 250 nM MLN4924 as indicated. Values shown represent the
means 6 SD of viable cells. C) Cells (56103/well) were seeded in 96-well plates and treated with increasing concentrations of MLN4924 for 72 hours.
After incubation, cell viability was assessed by the CellTiter Glo assay. Values shown represent the mean percentage 6 SD of viable cells relative to
vehicle controls. R-K562MLN-5W, R-K562MLN cells that were maintained in MLN4924-free medium for 5 weeks. D) Cells (5610
3/well) were plated in 96-
well plates and treated with increasing concentrations of chemotherapeutic drugs as indicated for 72 hours. Cell growth and viability was assessed
by the MTS assay. Values shown represent the mean percentage 6 SD of viable cells relative to vehicle controls.
doi:10.1371/journal.pone.0093530.g001
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[GAG (Glutamic Acid, E).GTG (Valine, V)] and a T.A
mutation in codon 310 [ATT (Isoleucine, I).AAT (Asparagine,
N)] (Figure 3A). Importantly, the homozygous I310N mutation
was not present upon sequencing UBA3 cDNA of parental K562
cells. However, the E8V mutation was present in both parental
and R-K562MLN cells. Thus, the E8V mutation is likely not
responsible for the observed resistance in the R-K562MLN cells. By
virtual modeling, I310 is located in the active site of NAE, but is
not part of the adenylation pocket. Rather, it lies in the hinge
region of the ThiF domain and insertion domain, forming an
aliphatic interaction with the penultimate glycine of NEDD8
bound in the adenylation pocket (Figure 3B). Of note, sequence
alignment showed that the I310 is conserved from mammals to
yeast. Moreover, the residue is conserved in other E1 enzymes
(Figure 3C), further supporting the functional importance of the
I310N mutation.
UBA3 I310N mutation alters NAE biochemical properties
to reduce MLN4924 sensitivity
To explore the effects of the I310N mutation on the activity of
NAE and its sensitivity to MLN4924, we generated recombinant
wild-type and I310N NAE complexes and evaluated these using an
ATP:PPi exchange assay [27,31]. This assay measures the
synthesis of radiolabeled ATP from input radiolabeled pyrophos-
phate (PPi) by NAE in a NEDD8, ATP, and PPi dependent
manner, allowing for the quantitative assessment of biochemical
properties of the enzyme through titration experiments.
As high concentrations of NEDD8 inhibit ATP synthesis by
NAE [31], we first performed NEDD8 titrations to evaluate the
effects of the I310N mutation on the reaction rate (Figure 3D;
raw data shown in Figure S1A in File S1). NAE with UBA3
I310N requires higher NEDD8 concentrations than NAE to
achieve its maximum rate (6.25 mM and 1.56 mM, respectively),
indicating a lower affinity for NEDD8. However, at these NEDD8
concentrations, the maximum rate for the I310N complex is ,5-
fold higher (16.9 pmol/min and 3.3 pmol/min).
Using these NEDD8 concentrations, we next evaluated the
effects of ATP (Figure 3E and Figure S1B in File S1) and PPi
(Figure 3F and Figure S1C in File S1) in the assay. We found
that the I310N mutation decreased the KM for ATP of NAE 4-fold
(20 mM and 80 mM for the I310N and wild-type complexes,
respectively) while the KM for PPi increased ,10-fold (51.1 mM
and 5.0 mM). These data are consistent with the I310N complex
having a higher affinity for ATP and lower affinity for PPi than the
wild-type enzyme.
To evaluate how these biochemical changes impact the
enzyme’s sensitivity to MLN4924, we performed MLN4924
titration experiments (Figure 3G and Figure S1D in File S1).
Consistent with a direct role for the I310N mutation in conferring
MLN4924 resistance in cells, this NAE complex was ,7-fold less
sensitive to MLN4924 than wild-type (MLN4924 IC50 values are
225 nM and 32 nM, respectively). Together, these biochemical
changes in NAE—decreased NEDD8 and PPi affinities, increased
ATP affinity, and an increased rate of ATP synthesis— provide a
Figure 2. MLN4924-resistant K562 cells show decreased inhibition of cullin neddylation by MLN4924 but remain sensitive to
knockdown of NEDD8. A) Cells were treated with increasing concentrations of MLN4924 as indicated for 24 hours. After treatment, total cell
lysates were prepared and analyzed by SDS-PAGE and immunoblotting using anti-NEDD8 and anti-a-tubulin antibodies to detect NEDD8-cullin
complexes and equal protein loading, respectively. B) Cells were infected with lentiviral vectors expressing three independent shRNA sequences
targeting NEDD8 (shNEDD8) or a control sequence (shControl), and successfully transduced puromycin-resistant populations were selected. Total cell
lysates were prepared and analyzed by SDS-PAGE and immunoblotting with antibodies against NEDD8 and a-tubulin. C) Cells infected with vectors
containing shNEDD8 or control sequences and selected for puromycin resistance were seeded in 6-well plates (16105 cells/ml). After incubation for 2,
3, and 6 days, cell growth and viability were assessed by trypan blue exclusion. Values represent the mean percentage6 SD of viable cells relative to
cells infected with control sequences.
doi:10.1371/journal.pone.0093530.g002
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mechanistic basis for acquired MLN4924 resistance found in
K562 cells through the UBA3 I310N mutation.
The significant effect of the I310N mutation on kinetics and
MLN4924 inhibition is consistent with the fact that this residue is
involved in the first and likely rate-limiting step of neddylation, as
it forms direct interaction with the diglycine motif of NEDD8
(Figure 3B, panels 1 and 2).
U937 leukemia cells become resistant to MLN4924
through a UBA3 mutation distinct from that found in
K562 cells
Having identified a mutation in the UBA3 gene that supports
MLN4924 resistance in K562 cells, we asked whether another
malignant hematologic cell line employs a similar on-target
resistance mechanism. We choose U937 cells as this cell line has
been used extensively as a model to study hematological
Figure 3. cDNA sequencing reveals missense point mutations in the UBA3 coding region of MLN4924-resistant K562 cells which
decrease the sensitivity of NAE to MLN4924 in vitro. A) Total cellular RNA was isolated from parental and MLN4924-resistant R-K562MLN cells.
UBA3 cDNA spanning its entire coding region was amplified by RT-PCR and then sequenced. The nucleotide sequence from codon 307 to 313 for
K562 (left panel) and R-K562MLN (right panel), three letter amino acid codes, and codon numbers are each shown above the sequence
electropherogram tracing. Arrows indicate the position of the second nucleotide of the codon 310 in which the single nucleotide shift (TR A) in R-
K562MLN occurred. B) Stereoscopic views of NAE and SAE active sites. Enzymes are shown in cyan ribbon format with either NEDD8 or SUMO UBL in
green stick format. Secondary structure elements are labelled. 1) The NAE active site from the PDB= 2NVU structure is shown with NEDD8 and ATP.
Also in stick format is I310, which mutated to asparagine renders the enzyme more active than wild type and resistant to MLN4924. For comparison,
four other mutations that render resistance are shown in red line format. 2) The PDB= 3GZN structure is shown with the NEDD8-MLN4924 adduct.
Also shown in line format are side chains of residues nearby. 3) The SUMO-AMP adduct of SAE from PDB=3KYC shows that a similar isoleucine (I384)
is positioned near the diglycine motif of the UBL. 4) The covalent cysteine intermediate, captured by PDB= 3KYD, shows that I384 must be displaced
for reaction to proceed. C) Sequence alignment of human UBA3, UBA1, UBA2, and UBA6 was performed, and residues corresponding to UBA3’s I310
are shaded. D) NEDD8 (2-fold dilutions from 50 mM) was added to ATP:PPi exchange reactions containing 20 nM NAE or NAE (UBA3 I310N), 1 mM
ATP, and 100 mM PPi (supplemented with 50 cpm/pmol [32P] PPi). After 30 min at 37uC, radiolabeled ATP generated was measured. Error bars
represent SEM (n= 3). Bar graphs indicate the NEDD8 concentration and maximum observed rate for the enzymes. The effects of ATP (E) and PPi (F)
on ATP synthesis were evaluated using either 1.56 mM NEDD8 (NAE) or 6.25 mM NEDD8, determined from (D). ATP concentrations tested were 2-fold
dilutions from 2 mM with 100 mM PPi. PPi concentrations were 2-fold dilutions from 0.5 mM with 1 mM ATP. G)MLN4924 was tested (3-fold dilutions
from 200 mM, 2% DMSO final concentration) in reactions containing 20 nM NAE or NAE (UBA3 I310N), 1 mM ATP, 100 mM PPi, and NEDD8. The
measured IC50 from non-linear regression analyses of triplicate experiments is shown. Error bars represent SEM.
doi:10.1371/journal.pone.0093530.g003
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malignancies. We selected a population of U937 leukemia cells
resistant to MLN4924 using the method established for K562 cells
described above. In cell growth and viability assays, parental U937
cells are sensitive to MLN4924 with an EC50 value of 25 nM,
while MLN4924-resistant R-U937MLN cells are more than 50-fold
less sensitive to MLN4924 (Figure 4A). In immunoblot assays,
loss of NEDD8-conjugated cullins is observed in parental cells
after treatment with 25 nM of MLN4924 for 24 hours
(Figure 4B), while no significant reduction in the abundance of
NEDD8-cullin conjugates occurs in the resistant cells after
treatment with 50 nM MLN4924 (Figure 4B).
To determine whether UBA3 mutations may be associated with
resistance to MLN4924 in R-U937MLN, we sequenced the coding
region of UBA3 in the parental and R-U937MLN cells. We
identified a single point mutation in codon 352 [TAT (Tyrosine,
Y) . CAT (Histidine, H)] only in the resistant cells (Figure 4C).
As there are two overlapping traces representing either the T or C
nucleotide at the same position in codon 352 (Figure 4C), these
cells are heterozygous for the Y352H mutation.
Unlike I310, the Y352 residue is not conserved in other E1
enzymes. However, Y352 is conserved as an aromatic residue from
mammals to yeast (Figure 4D). In examining the location of
Y352 in the NAE structure, this residue is located at the base of the
NEDD8 binding pocket, about 20 A˚ away from I310, where its
side chain forms van der Waals interactions with the b1-b2 loop of
NEDD8 (Figure 4E).
Figure 4. MLN4924-resistant U937 leukemia cells show reduced sensitivity to MLN4924 and are heterozygous for a UBA3 mutation
Y352H. A) Cells (16104 cells/well) were seeded in 96-well plates and incubated with increasing concentrations of MLN4924 for 72 hours. After
incubation, cell viability was measured by the CellTiter-Glo assay. Values shown are the mean percentage 6 SD of viable cells relative to controls. B)
Cells were treated with increasing concentrations of MLN4924 as indicated for 24 hours followed by isolation of total cellular proteins. Equal amounts
of proteins were fractionated by SDS-PAGE and analyzed by immunoblotting with anti-NEDD8 and anti-a-tubulin antibodies. C) UBA3 cDNA in
parental and MLN4924-resistant R-U937MLN cells was sequenced as described in Figure 4. Shown are the nucleotide sequence from codons 347 to 354
for U937 (left panel) and R-U937MLN cells (right panel), three letter amino acid codes, and codon numbers. Arrows depict the position of the first
nucleotide of the codon 352 in which the single nucleotide shift (T R C) in R-U937MLN occurred. D) Sequence alignment of UBA3s from different
organisms was performed, and residues corresponding to the Y352 are shaded. E) The Y352H mutation. To the left the NAE heterodimer surface is
shown in grey and its subdomains labelled. Phe352 is shown in magenta. Bound NEDD8 is shown in green ribbon format. On the right, a close-up of
the interface between NAE (cyan) and NEDD8 (green) is shown in ribbon format. Shown in line format are residues within proximity.
doi:10.1371/journal.pone.0093530.g004
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The Y352H mutation reduces MLN4924 potency on NAE
through decreased NEDD8 and increased ATP affinities
We compared the rate of ATP synthesis for NAE and NAE
(UBA3 Y352H) in the ATP:PPi exchange assay (Figure 5).
Similar to NAE with the I310N mutation, the Y352H enzyme
requires higher NEDD8 concentrations than wild-type (6.25 mM
and 1.56 mM) to achieve its maximum rate (Figure 5A and
Figure S2A in File S1). In contrast, however, this rate is ,1.4-
fold lower than wild-type NAE.
In ATP titration experiments (Figure 5B and Figure S2B in
File S1), we found that the Y352H mutation decreases the
enzyme’s ATP KM ,3-fold (27 mM and 80 mM for Y352H and
wild-type complexes), similar to what we observed with the
complex containing I310N (see Figure 3E). However, we found
no significant differences in the PPi KM (Figure 5C and Figure
S2C in File S1) for the Y352H complex in comparison to wild-
type (10.9 mM and 9.5 mM, respectively), distinct from what we
observed with the I310N-containing complex (see Figure 3F). In
testing this NAE complex with increasing concentrations of
MLN4924 (Figure 5D), we found that the Y352H mutation
confers a,10-fold decrease in the sensitivity of NAE to MLN4924
(IC50 values 138.5 nM and 13 nM for the Y352H enzyme and
wild-type, respectively). These biochemical experiments suggest
that the Y352H mutation, like I310N, is sufficient to provide
MLN4924 resistance in leukemia cells. Thus, differences in the
affinity for PPi may underlie observed differences in ATP synthesis
rates between the Y352H and I310N enzyme complexes.
Nevertheless, these findings suggest that mutations located in
different positions around the NEDD8 binding site of UBA3 cause
changes in the catalytic pocket of the enzyme to reduce MLN4924
potency while allowing sufficient NEDD8 system function for
leukemia cell survival.
Figure 5. The Y352H mutation is sufficient to decrease the sensitivity of NAE to MLN4924 in vitro. NEDD8 (A), ATP (B), PPi (C), and
MLN4924 (D) titrations were performed using the ATP:PPi exchange assay to compare ATP synthesis by NAE (UBA3 Y352H) to NAE. Assay conditions
were as described in Figure 3. Experiments were performed in triplicate with error bars representing SEM.
doi:10.1371/journal.pone.0093530.g005
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The pan-E1 inhibitor Compound 1, but not NAE-selective
analogues, is active on MLN4924-resistant leukemia cells
Compound 1 is a MLN4924 analogue initially characterized by
Millennium Pharmaceuticals (The Takeda Oncology Company)
[18]. In contrast with MLN4924, Compound 1 is a pan-E1
inhibitor and is capable of inhibiting a panel of E1 enzymes,
including NAE, UBA1 (ubiquitin E1), and UBA2 (SUMO E1)
[18,34]. Through previous structure-activity relationship studies,
we generated a library of indane-substituted Compound 1
analogues and identified several that are NAE selective [35].
We tested these NAE-selective Compound 1 analogues on R-
K562MLN cells in viability assays (Figure 6A; Table S2 in File
S1). Although these all have varying potency on the parental K562
cells, which presumably reflect differences in NAE binding
mediated by the indane substitutions, the MLN4924-resistant
cells are highly cross-resistant to these inhibitors (Figure 6A;
Table S2 in File S1). In immunoblot assays, no significant
reduction in the steady state abundance of NEDD8-cullin
conjugates was observed in R-K562MLN cells after treatment with
these inhibitors for 24 hours at concentrations of 2-fold their
respective EC50 values in the parental cells, while essentially
complete loss of NEDD8-conjugated cullins occurred in parental
cells after the treatment (data not shown).
Given that Compound 1 has a broad selectivity profile for other
E1s, we reasoned that this molecule may remain cytotoxic to R-
K562MLN cells. In comparing the effects of Compound 1 on the
parental and R-K562MLN cells in cell viability assays (Figure 6B),
we found the resistant cells are not refractory to Compound 1
(EC50 values of 27 nM and 81 nM respectively). We hypothesize
that the 3-fold higher EC50 value obtained is due to the inability of
Compound 1 to inhibit NAE containing the UBA3 I310N
mutation.
In testing this possibility by immunoblotting, extracts from
Compound 1 treated cells (Figure 6C), we found that parental
and R-K562MLN cells have similar changes in ubiquitin conjugates
in response to increasing concentrations of Compound 1 while
NEDD8-modified cullins in the MLN4924 resistant cells are
unaffected. These data are consistent with Compound 1 inhibiting
the ubiquitin pathway through UBA1 (and presumably the
SUMO E1) in both cell lines, while NAE is only inhibited in the
parental K562 cells.
Leukemic cells in a relapsed AML patient after treatment
with MLN4924 do not harbor mutations in the UBA3
gene
Currently, MLN4924 is being evaluated in early phase clinical
trials in patients with hematologic malignancies. These early trials
are showing promising clinical efficacy in patients with relapsed
and refractory AML [25]. To investigate whether UBA3
mutations can explain resistance to MLN4924, we sequenced
UBA3 cDNA in a patient with refractory AML who relapsed after
an initial response to MLN4924 therapy. An 82-year-old man was
diagnosed with therapy-related AML following radiation therapy
targeting a localized prostate carcinoma. After progressing on 5-
azacitidine, he initiated treatment with MLN4924 at 33 mg/m2
intravenously on days 1, 4, 8 and 11 every 21 days in a Phase I
trial of the drug (NCT00911066, registered at ClinicalTrials.gov).
MLN4924 treatment was well tolerated, and the patient complet-
ed 12 cycles of therapy without drug-related adverse events. The
patient achieved a partial response following 8 cycles of MLN4924
therapy and a complete remission with incomplete peripheral
blood recovery after 10 cycles of therapy. Unfortunately, the
patient relapsed after completion of 12 cycles of treatment.
Samples of peripheral blood and bone marrow were obtained
from the time of diagnosis and relapse, respectively. Mononuclear
cells were isolated from the samples and total RNA was extracted.
UBA3 cDNA was amplified by Q-RT-PCR and the entire coding
region of UBA3 was sequenced and analyzed. No UBA3
mutations were detected at relapse, indicating that relapse of this
patient after an initial response to MLN4924 was not caused by a
mutation in this gene.
Discussion
Protein modifications by NEDD8 have important functions
promoting cancer cell survival as discovered from pre-clinical
studies using the first-in-class NAE inhibitor MLN4924 [17,20]. In
this study, we explored the mechanisms of acquired resistance to
MLN4924 using human leukemia cell lines, as early clinical data
suggest hematologic malignancies may be the major indication for
the drug. We found that both K562 and U937 leukemia cells
became resistant to MLN4924 after prolonged exposure to
increasing concentrations of the drug. These resistant cells still
require NEDD8 for survival, as knockdown of the NEDD8 protein
with shRNA decreased viability similar to parental cells.
Inhibition of the neddylation system by MLN4924 requires an
active NAE that catalyzes the formation of the inhibitory NEDD8-
MLN4924 adduct [26]. This is a unique characteristic of the
mechanism-based inhibition of NAE by MLN4924. In our study,
we identified two different point mutations in the UBA3 gene of
the resistant cell lines that impact NEDD8 binding. We showed
that the mutations alter the biochemical properties of NAE. Both
increase NAE’s affinity for ATP while requiring higher NEDD8
concentrations for optimal ATP synthesis. Collectively, these
features decrease the potency of MLN4924 in vitro and provide a
mechanistic basis for the decreased sensitivity of leukemia cells to
MLN4924 through these single amino acid mutations.
In addition to the identification of the UBA3 I310N mutation
that rendered K562 cells resistant to MLN4924, we also
demonstrated that the MLN4924-resistant U937 cells harbor an
Y352H mutation in the UBA3 gene. Our results suggest that
mutations in the UBA3 gene are a common mechanism for
malignant leukemia cells to acquire resistance to MLN4924 in
vitro. However, there is a possibility that additional mechanisms
are contributing to MLN4924 resistance. While we did not identify
any mutations in the coding region of NEDD8, we cannot exclude
the possibility that other members of NEDD8 conjugation
pathway can also contribute to the development of MLN4924
resistance.
Recently, we and another group have reported the identification
of additional MLN4924-induced mutations in the UBA3 gene in
several cancer cell lines [26,27]. Interestingly, mutation at the
A171 residue identified in MLN4924 resistant HCT116 colon
cancer cell line by both groups was not identified in the two
leukemic cell lines used in our current study. It is possible that
MLN4924 resistance mutations are tissue specific, especially given
that A171 and I310 mutations are located in different regions of
UBA3. The A171T mutation is located in the UBA3 nucleotide
binding site; other mutations detected by Milhollen et al occur at
various residues in the NEDD8 binding site of UBA3. Mutations
at these sites reduce NEDD8-MLN4924 adduct formation and
binding to the NAE [26,27]. Rather than lying in the nucleotide or
NEDD8 binding sites, the I310N mutation identified in our study
lies in the hinge region between the ThiF domain and insertion
domain of UBA3. The I310 residue forms an aliphatic interaction
with the penultimate glycine of NEDD8 bound in the adenylation
pocket and may therefore modulate the motion of the insertion
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domain and the transition of the enzyme from the closed to open
state. Mutations in the I310 residue could thereby either produce a
physical change in enzyme conformation, or alter the rate at which
the insertion domain covers and uncovers the adenylation pocket.
It is interesting to note, that the increase in the NAE’s affinity
for ATP in the presence of UBA3 mutations as a resistance
mechanism to MLN4924 is reminiscent of the similar drug
resistance mechanism in epidermal growth factor receptor (EGFR)
mutant. The T790M EGFR mutant has increased affinity for
ATP, which is the primary mechanism responsible for the
development of resistance to small molecule tyrosine kinase
inhibitors (TKIs), such as gefitinib and erlotinib [36]. Since, TKIs
compete with ATP in a reversible manner to bind to EGFR, the
mechanism of T790M EGFR resistance can be overcome by using
second-generation irreversible EGFR inhibitors. Thus, there is a
possibility that MLN4924 resistance in UBA3 mutants can be
overcome by more potent second-generation NAE inhibitors.
Compound 1, a pan-E1 inhibitor, is capable of inhibiting the
enzymatic activity of UBA1, UBA2, and NAE with equal potency
[18]. Our studies demonstrated that Compound 1 remained
cytotoxic to MLN4924-resistant cells that were also cross-resistant
to other selective NAE inhibitors. The cytotoxicity of Compound 1
towards the MLN4924-resistant cells might be explained by its
inhibition of other E1 enzymes. Indeed, we demonstrated that
Compound 1 diminishes the abundance of ubiquitinated proteins
in the resistant cells similar to its effects in parental cells. Thus,
pan-E1 inhibitors may overcome resistance to MLN4924 by
targeting other E1 enzymes.
It currently remains unknown whether spontaneous or acquired
mutations in the UBA3 gene confer resistance to MLN4924 in
patients treated with this drug. To our knowledge, we are the first
to report the results of sequencing the UBA3 gene in an AML
patient who relapsed after achieving remission with MLN4924
treatment. No mutations in UBA3 were detected at either
diagnosis or relapse. Thus, additional mechanisms must account
for relapse in this patient. Larger numbers of relapsed patients will
be needed to determine whether acquired or spontaneous
mutations in UBA3 are a clinically relevant cause of relapse.
In summary, we have identified two mutations in UBA3 which
were not previously reported or characterized and demonstrated
that these mutations confer MLN4924 resistance in leukemia cell
lines but do not impair normal function of the NAE enzyme and
Figure 6. MLN4924-resistant cells are sensitive to the pan-E1 inhibitor Compound 1, but are resistant to NAE-selective Compound 1
analogues. A) Cells were seeded in 96-well plates (36103 cells/well) and treated with increasing concentrations of various selective NAE inhibitors
for 72 hours. After treatment, cell viability was assessed by the CellTiter Glo assay. Values shown are the mean percentage6 SD of viable cells relative
to vehicle controls. EC50 values calculated from the dose-response curves of the parental K562 cells presented here have been presented in a previous
publication by Lukkarila et al [35]. B) Parental K562 and MLN4924-resistant R-K562MLN cells were plated in 96-well plates (5610
3 cells/well) and
treated with increasing concentrations of compound 1 for 72 hours. After incubation, cell viability was measured by the CellTiter Glo assay. Values
shown are the mean percentage6 SD of viable cells relative to controls. C) K562 and R-K562MLN cells were treated with increasing concentrations of
compound 1 for 24 hours. After treatment, total cellular proteins were analyzed by SDS-PAGE and immunoblotting with anti-NEDD8, anti-ubiquitin
(Ub) and anti-a-tubulin antibodies.
doi:10.1371/journal.pone.0093530.g006
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activity of the neddylation pathway. As MLN4924 continues to be
evaluated clinically, our work provides valuable insights that may
help detection of MLN4924-resistant malignancies and facilitate
the development of second-generation NAE inhibitors to over-
come MLN4924 resistance.
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